CliffBio
small molecule

SYNDROS

DRONABINOL

Loss of exclusivityAugust 2028latest FDA-listed patent expiry
CompanyWellHouse →See this company's full patent-cliff portfolio

Drug detail

Brand nameSYNDROS
Active ingredientDRONABINOL
Strength5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
10265293August 2028substance, product
9345771August 2028substance, product
11253472August 2028substance, product
8222292August 2028substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYNDROS patent cliff — loss of exclusivity August 2028 | CliffBio